Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2022-01-18 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
独立董事关于第九届董事会临时会议的独立意见
Board/Management Information Classification · 95% confidence The document is a statement of independent directors' opinions regarding a board meeting resolution about capital increase in a subsidiary. It references regulatory guidelines for independent directors and corporate governance but does not contain financial statements or detailed financial data. The document is short (381 characters) and is an opinion related to a board meeting decision, not a full report or announcement of voting results. It fits best under Board/Management Information (MANG) as it relates to board-level decisions and opinions.
2022-01-18 Chinese
独立董事关于第九届董事会临时会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is a statement of independent directors' opinions regarding a specific board meeting resolution about the company's acquisition of a 3.7789% equity stake in another company. It references regulatory guidelines related to independent directors and corporate governance but does not contain financial statements or detailed financial data. The document is focused on board/management information, specifically the independent directors' approval of a board decision. It is not an annual report, audit report, earnings release, or any other financial report. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and contains a formal opinion from independent directors, which fits the MANG category.
2021-12-17 Chinese
第九届董事会临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed at a board meeting regarding the company's decision to acquire a 3.7789% equity stake in another company. It includes details about the meeting date, voting results, and references to a related public announcement. The content focuses on board decisions and management actions rather than financial results, audit information, or shareholder voting outcomes. It is not a full report, earnings release, or regulatory filing but specifically relates to board/management decisions. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and contains detailed board meeting resolution information, confirming this classification with high confidence.
2021-12-17 Chinese
关于对外投资暨受让观然医疗部分股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding an external investment by the company (启迪药业集团股份公司) to acquire a 3.7789% equity stake in another company (观然医疗). It details the investment overview, transaction counterparties, investment target information, financial data of the target, contract terms, risks, and impact on the company. There are no financial statements or comprehensive financial performance data of the reporting company itself. The document is a formal announcement of a capital investment transaction, specifically a share acquisition. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is over 5,000 characters and contains substantive details about the transaction, not just a brief notice or report publication announcement. Therefore, the correct classification is CAP with high confidence.
2021-12-17 Chinese
关于对外投资设立合资公司的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement by a company about its external investment to establish a joint venture company. It details the investment overview, counterpart introduction, basic information of the investment target, main contract contents, and the purpose and risks of the investment. There are no financial statements, quarterly or annual results, or audit information. The document is an announcement of a corporate action related to capital investment but does not describe financing activities like fundraising or capital structure changes. It is not a report or presentation but a regulatory announcement about a corporate investment transaction. Therefore, the most appropriate classification is a Regulatory Filing (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2021-12-10 Chinese
关于使用部分闲置募集资金购买的理财产品到期赎回并继续进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the use of idle raised funds to purchase financial products, including details of purchases, redemptions, risk control measures, and approvals by the board and shareholders. It is a progress update on cash management activities related to fundraising proceeds, not a full financial report or audit. The document length is 3754 characters, relatively short, and it primarily discloses specific financing and investment activities related to capital management. This fits the category of Capital/Financing Update (CAP) rather than a full Annual Report, Interim Report, or Regulatory Filing. There is no indication that this is a report publication announcement or a certification. Therefore, the best classification is CAP with high confidence.
2021-12-10 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.